Aclidinium/formoterol [1], IMAOs ---> SmPC of [1] of EMA
Duaklir Genuair should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval because the action of formoterol on the cardiovascular system may be potentiated
Adrenaline [1], IMAOs ---> SmPC of [1] of eMC
Concurrent use or use of adrenalin within 2 weeks of monoamine oxidase inhibitor increases risk of adverse events.
Alaproclate, IMAOs
Combination (contraindicated) may cause serious and sometimes fatal reactions. After discontinuing MAOI, wait (depending on IMAO) 5/2 weeks or 1 day before administering SSRI
Alfa2-adrenergic agonists, IMAOs
MAOI may enhance the hypertensive effect of adrenergic alpha2-agonist. The concomitant use is contraindicated.
Alfentanyl, IMAOs
Possible severe side effects on the CNS and side effects on the respiratory and circulatory function. IMAO should be avoided within 2 weeks before a surgical operation
Alimemazine, IMAOs
There may be increased antimuscarinic and sedative effects of phenothiazines
Almotriptan [1], IMAOs ---> SmPC of [1] of eMC
As with other 5-HT1 agonists, the potential risk of a serotoninergic syndrome due to a pharmacodynamic interaction in case of concomitant treatment of almotriptan with MAOIs cannot be ruled out.
Altretamine, IMAOs
The co-administration may cause symptomatic hypotension
Amezinium, IMAOs
Enhancement of sympathomimetic effect
Amfepramone, IMAOs
The indirect sympathomimetic effect of amfepramone may be dangerously enhanced by MAO inhibitors and during the last 14 days after last taking the MAO inhibitors
Amiodarone, IMAOs
The concomitant use is contra-indicated
Amitriptyline [1], IMAOs ---> SmPC of [1] of eMC
Severe convulsions and fatalities have occurred. Amitriptyline should not be given with a MAOI, and a minimum of 14 days should elapse between discontinuing a MAOI and starting amitriptyline.
Amphetamine [1], IMAOs ---> SmPC of [1] of eMC
Amfetamine should not be administered during or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) because it can increase the release of norepinephrine and other monoamines.
Anorexics, IMAOs
The anorexiant should not be used with a MAOI
Anticholinergics, IMAOs
Monoamine oxidase inhibitors can interact with concurrently administered anticholinergic agents. This can cause dry mouth, blurred vision, urinary hesitancy, urinary retention and constipation.
Antidepressants, IMAOs
The combination should be avoided due to increased risk of hypertension
Antiepileptics, IMAOs ---> SmPC of [ethosuximide] of eMC
The anticonvulsant effect of antiepileptic agents may be antagonized by MAO inhibitors (convulsive threshold lowered)
Antihistamines, IMAOs
The co-administration of dimetindene and MAO inhibitors may enhance the antimuscarinic and CNS depressant effects of antihistaminics. The co-administration is not recommended
Apraclonidine [1], IMAOs ---> SmPC of [1] of eMC
Apraclonidine is contraindicated in patients receiving monoamine oxidase inhibitors
Articaine/epinephrine, IMAOs
The sympathomimetic effect of epinephrine may be potentiated with the simultaneous intake of MAO inhibitors and are contraindicated
Atenolol, IMAOs
Combination of a MAO inhibitor with a beta-blocker can cause an increase of the pharmacodynamic effects and an increase in blood pressure up to hypertension crises.
Atenolol/chlortalidone, IMAOs
Excessive increase of the blood pressure (except MAO B)
Atenolol/nifedipine, IMAOs
Combination of a MAO inhibitor with a beta-blocker can cause an increase of the pharmacodynamic effects and an increase in blood pressure up to hypertension crises.
Atomoxetine, IMAOs
Atomoxetine should not be used in combination with MAOIs. Atomoxetine should not be used within a minimum of 2 weeks before initiation nor 2 weeks after discontinuing therapy with MAOI
Atropine, IMAOs
Monoamine oxidase inhibitors enhance the effect and toxicity of atropine
Avocat, IMAOs
The concomitant intake may cause hypertensive crisis
Bamethane, IMAOs
Sympathomimetics are absolutely contraindicated during a treatment with a MAO inhibitor and within at least 14 days of discontinuing MAOI treatment.
Banane, IMAOs
The concomitant intake may cause hypertensive crisis
Barbiturates, IMAOs
The MAOI may enhance the effects of barbiturate
Beclometasone/formoterol/glycopyrronium, IMAOs [2] ---> SmPC of [2] of EMA
Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias.
Bendroflumethiazide, IMAOs
Concomitant use of bendroflumethiazide with monoamine oxidase inhibitors (MAOIs) may give an increased hypotensive effect.
Benzodiazepines, IMAOs
The co-administration may enhance the depressive effect on the central nervous system (e.g. increased sedation, respiratory depression)
Beta-adrenergic agonists, IMAOs
Beta-adrenergic agonists should be used with caution in patients treated with MAO inhibitors as the effect of beta-adrenergics may be enhanced
Betablockers, IMAOs ---> SmPC of [bisoprolol] of eMC
Combination of a MAO inhibitor with a beta-blocker can cause an increase of the pharmacodynamic effects and an increase in blood pressure up to hypertension crises.
Betahistidine, IMAOs
In vitro data indicate an inhibition of betahistine metabolism by drugs that inhibit monoamino-oxidase (MAO) including MAO subtype B (e.g. selegiline).
Betahistine [1], IMAOs ---> SmPC of [1] of eMC
Caution is recommended when using betahistine and MAO inhibitors concomitantly.
Bezafibrate [1], IMAOs ---> SmPC of [1] of eMC
MAO-inhibitors (with hepatotoxic potential) should not be administered together with bezafibrate.
Bisoprolol [1], IMAOs ---> SmPC of [1] of eMC
Concomitant use of monoamine oxidase inhibitors (except MAO-B inhibitors) and bisoprolol enhances hypotensive effect of the beta-blocking agents, but also risk for hypertensive crisis.
Brimonidine [1], IMAOs ---> SmPC of [1] of EMA
The co-administration of brimonidine with MAOI is contraindicated
Brinzolamide/brimonidine [1], IMAOs ---> SmPC of [1] of EMA
Brinzolamide/brimonidine is contraindicated in patients receiving monoamine oxidase inhibitors
Bromhexine, IMAOs
Bronchial secretion inhibitors may antagonize the effects of bromhexine
Bromocriptine, IMAOs
Decreased effect of bromocriptine
Budesonide/formoterol [1], IMAOs ---> SmPC of [1] of EMA
Concomitant treatment of formoterol with MAO inhibitors may prolong the QTc-interval and increase the risk of ventricular arrhythmias and also precipitate hypertensive reactions.
Buprenorphine, IMAOs [2] ---> SmPC of [2] of EMA
Possible exacerbation of the opioids effects, based on experience with morphine.
Buprenorphine/naloxone [1], IMAOs ---> SmPC of [1] of EMA
The concomitant use of monoamine oxidase inhibitors (MAOI) might produce exaggeration of the effects of opioids, based on experience with morphine.
Bupropion [1], IMAOs ---> SmPC of [1] of eMC
Since MAO A and B inhibitors also enhance the catecholaminergic pathways, by a different mechanism from bupropion, concomitant use is contraindicated as there is an increased possibility of adverse reactions from their co-administration.
Buspirone [1], IMAOs ---> SmPC of [1] of eMC
Co-administration of MAO inhibitors may cause increases in blood pressure. Co-administration of MAO inhibitors and buspirone is therefore not recommended
Carbamazepine [1], IMAOs ---> SmPC of [1] of eMC
The use of carbamazepine is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs); before administering carbamazepine MAOIs should be discontinued for a minimum of 2 weeks, or longer if the clinical situation permits
Carvedilol [1], IMAOs ---> SmPC of [1] of eMC
Concomitant treatment of carvedilol with monoamine oxidase inhibitors (exception MAO-B inhibitors) can lead to additional decrease in heart rate. A monitoring of vital signs is recommended.
Cathine, IMAOs
The indirect sympathomimetic effect of cathine may be dangerously enhanced by MAO inhibitors and during the last 14 days after last taking the MAO inhibitors
Celiprolol [1], IMAOs ---> SmPC of [1] of eMC
There is a theoretical risk that concurrent administration of monoamine oxidase inhibitors and high doses of beta-adrenoceptor blockers, even if they are cardio selective, can produce hypotension and is therefore not recommended.
Cheese, IMAOs
The concomitant intake may cause hypertensive crisis
Chloral hydrate, IMAOs
The co-administration may enhance the effect of chloral hydrate
Chlordiazepoxide, IMAOs
Additive effect
Chloroquine, IMAOs
The co-administration of chloroquine with MAOI is not recommended
Chlorphenamine, IMAOs
MAOI therapy intensifies the anticholinergic effects of chlorphenamine. The co-administration is contraindicated
Chlorpropamide, IMAOs
Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia
Chlorprothixene, IMAOs
The enzymatic inhibition increases the plasma levels of chlorprothixene
Chocolate, IMAOs
The concomitant intake may cause hypertensive crisis
Citalopram [1], IMAOs ---> SmPC of [1] of eMC
Simultaneous use of citalopram and MAOI can result in severe side effects, including serotonin syndrome. Cases of serious and sometimes fatal reactions have been reported in patients who have recently discontinued an SSRI and have been started on a MAOI.
Clebopride, IMAOs
The co-administration may increase the risk of adverse reactions
Clemastine [1], IMAOs ---> SmPC of [1] of eMC
Antihistamines potentiate the sedative effects of monoamine-oxidase inhibitors (MAOI's)
Clenbuterol, IMAOs
The co-administration may enhance the effect of clenbuterol.
Clobenzorex, IMAOs
The co-administration of clobenzorex mit MAOI and within 2 weeks after MAOI discontinuation is contraindicated (hypertensive crisis)
Clomipramine [1], IMAOs ---> SmPC of [1] of eMC
Clomipramine must not be given in combination with or within 3 weeks before or after treatment with an MAO inhibitor
Cloperastine, IMAOs
Antihistaminics enhance the antimuscarinic effect. Cloperastine should not be used with MAO inhibitors
Clozapine [1], IMAOs ---> SmPC of [1] of eMC
Clozapine may enhance the central effects of CNS depressants
Codeine [1], IMAOs ---> SmPC of [1] of eMC
MAOIs due to the possible risk of excitation or depression - avoid concomitant use and for 2 weeks after discontinuation of MAOI
Cyclizine, IMAOs
The co-administration is contraindicated and 2 weeks after discontinuation of MAOI
Cyproheptadine [1], IMAOs ---> SmPC of [1] of eMC
MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.
Dapoxetine [1], IMAOs ---> SmPC of [1] of eMC
Dapoxetine should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, an MAOI should not be administered within 7 days after dapoxetine has been discontinued
Desflurane, IMAOs
Desflurane may potentiate the hypotensive effect when is administered with other antihypertensive drugs
Desloratadine/pseudoephedrine [1], IMAOs ---> SmPC of [1] of EMA
Risk of vasoconstriction and increased blood pressure. The co-administration is contraindicated
Dexchlorpheniramine, IMAOs
The co-administration of dexchlorpheniramine mit MAOI and within 2 weeks after MAOI discontinuation is contraindicated
Dextromethorphan [1], IMAOs ---> SmPC of [1] of eMC
Dextromethorphan is contraindicated in individuals who are taking, or have taken, monoamine oxidase inhibitors within the preceding 2 weeks
Dextromethorphan/quinidine [1], IMAOs ---> SmPC of [1] of EMA
Nuedexta must not be used with MAOIs, or in patients who have taken MAOIs within the preceding 14 days due to the risk of serotonin syndrome
Dextropropoxyphene, IMAOs
Possible enhancement of effect and toxicity of dextropropoxyphene
Diamorphine [1], IMAOs ---> SmPC of [1] of eMC
Concurrent use of diamorphine and monoamine oxidase inhibitors or within 2 weeks of their discontinuation is contraindicated
Dihydralazine, IMAOs
The co-administration may enhance the hypotensive and hypnotic effect
Dihydrocodeine [1], IMAOs ---> SmPC of [1] of eMC
The use of dihydrocodeine should be avoided while the patient is taking MAOIs and for 2 weeks after MAOI discontinuation.
Dimenhydrinate, IMAOs
The co-administration of dimenhydrinate and MAOIs may cause life-threatening enteroparesis, urinary retention, increased intraocular tension, hypotension, impaired function of CNS and respiration. The coadministration is contraindicated
Dimethindene, IMAOs
The co-administration of dimetindene and MAO inhibitors may enhance the antimuscarinic and CNS depressant effects of antihistaminics. The co-administration is not recommended
Diphenhydramine [1], IMAOs ---> SmPC of [1] of eMC
As diphenhydramine has some antimuscarinic activity, the effects of anticholinergic drugs may be potentiated therefore medical advice should be sought before taking diphenhydramine with such medicines.
Dipivefrine, IMAOs
The co-administration may increase the risk of adrenergic reactions
Dopamine [1], IMAOs ---> SmPC of [1] of eMC
MAO inhibitors potentiate the effect of dopamine and its duration of action. Patients who have been treated with MAO inhibitors prior to administration of dopamine will therefore require a substantially reduced dosage.
Dorzolamide/timolol [1], IMAOs ---> SmPC of [1] of eMC
There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic betablockers solution is administered concomitantly with monoamine oxidase (MAO) inhibitors
Doubutamine, IMAOs [2] ---> SmPC of [2] of eMC
Many sympathomimetics interact with MAOIs (possibility of hypertensive crisis), and should not be given to patients receiving such treatment or within 14 days of its termination.
Doxapram [1], IMAOs ---> SmPC of [1] of eMC
The action of doxapram may be potentiated after pre-treatment with a MAOI
Doxepin, IMAOs
It is known that monoamine oxidase inhibitors may potentiate other drug effects; therefore doxepin should not be given concurrently, or within 2 weeks of cessation of therapy, with monoamine oxidase inhibitors.
Doxylamine, IMAOs
The combination of doxylamine with other anticholinergic medicinal products may enhance the anticholinergic effects
Dronedarone [1], IMAOs ---> SmPC of [1] of EMA
MAO inhibitors might decrease the clearance of the active metabolite of dronedarone and should therefore be used with caution.
Ephedrine [1], IMAOs ---> SmPC of [1] of eMC
Non-selective MAO inhibitors: Paroxysmal hypertension, hyperthermia possibly fatal; the combination is contraindicated. Selective MAO-A inhibitors: Risk of vasoconstriction and/or episodes of hypertension; combination is not recommended
Epinephrine [1], IMAOs ---> SmPC of [1] of eMC
Concurrent use or use of adrenalin within 2 weeks of monoamine oxidase inhibitor increases risk of adverse events.
Esketamine [1], IMAOs ---> SmPC of [1] of EMA
Blood pressure should be closely monitored when Spravato is used concomitantly with psychostimulants or other medicinal products that may increase blood pressure
Eslicarbazepine [1], IMAOs ---> SmPC of [1] of EMA
An interaction between eslicarbazepine and MAOIs is theoretically possible
Ethosuximide, IMAOs
The anticonvulsant effect of antiepileptic agents may be antagonized by MAO inhibitors (convulsive threshold lowered)
Etilefrine, IMAOs
The co-administration may increase the effect of etilefrine. The combination is contraindicated
Etoperidone, IMAOs
Combination (contraindicated) may cause serious and sometimes fatal reactions. After discontinuing MAOI, wait (depending on IMAO) 5/2 weeks or 1 day before administering SSRI
Felodipine/metoprolol, IMAOs
Care should be taken when beta-blockers are given in combination MAO inhibitors.
Fenfluramine, IMAOs
The co-administration should be avoided. In extreme cases interactions may result in severe hypertensive episodes
Fenoterol, IMAOs
The co-administration may enhance the effect of adrenergic beta-agonist.
Fenproporex, IMAOs
The co-administration is contraindicated and during and until 14 days after treatment with a MAOI
Fentanyl [1], IMAOs ---> SmPC of [1] of EMA
Fentanyl is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
Fig, IMAOs
The concomitant intake may cause hypertensive crisis
Fluoxetine [1], IMAOs ---> SmPC of [1] of eMC
Cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with MAOI, and in patients who have recently discontinued an SSRI and have started on a MAOI.
Flupentixol, IMAOs
Caution is recommended with combine flupentixol and MAO inhibitors
Fluphenazine, IMAOs [2] ---> SmPC of [2] of eMC
Concurrent use of fluphenazine and MAO inhibitors may increase sedation, constipation, dry mouth and hypotension.
Fluvoxamine [1], IMAOs ---> SmPC of [1] of eMC
Fluvoxamine should not be used in combination with MAOIs
Formoterol, IMAOs ---> SmPC of [budesonide/formoterol] of EMA
Concomitant treatment of formoterol with MAO inhibitors may prolong the QTc-interval and increase the risk of ventricular arrhythmias and also precipitate hypertensive reactions.
Formoterol/glycopyrronium/budesonide [1], IMAOs ---> SmPC of [1] of EMA
Concomitant treatment can prolong the QT interval and increase the risk of ventricular arrhythmias. Concomitant treatment with monoamine oxidase inhibitors may precipitate hypertensive reactions.
Frovatriptan [1], IMAOs ---> SmPC of [1] of eMC
Frovatriptan is not a substrate for MAO-A, however a potential risk of serotonin syndrome or hypertension cannot be excluded. The co-administration is not recommended
Furazolidone, IMAOs
The co-administration may cause hypertensive crisis. The combination is contraindicated
Ginseng, IMAOs
Ginseng may enhance the effect of MAO inhibitors (hypertensive crisis, tremor, insomnia, headaches, mania)
Glibenclamide [1], IMAOs ---> SmPC of [1] of EMA
Potentiation of the blood-glucose lowering
Gliclazide [1], IMAOs ---> SmPC of [1] of eMC
Potentiation of the blood glucose lowering effect and thus, in some instances, hypoglycaemia may occur when MAOIs are taken
Glimepiride [1], IMAOs ---> SmPC of [1] of eMC
Potentiation of the blood-sugar-lowering effect and possible hypoglycaemia
Glipizide, IMAOs
The hypoglycaemic action of sulphonylureas in general may be potentiated by monoamine oxidase inhibitors
Gliquidone, IMAOs
Hypoglycemic reactions may occur as expression of enhancement effect of gliquidone with gliquidone is co-administered with antidepressive.
Glycopyrronium/indacaterol/mometasone [1], IMAOs ---> SmPC of [1] of EMA
This medicinal product should be administered with caution to patients being treated with monoamine oxidase inhibitors, as any effect of these on the QT interval may be potentiated.
Guanethidine, IMAOs
Guanethidine may lead to the release of large quantities of catecholamines, which may cause a hypertensive crisis. Monoamine oxidase inhibitors should be withdrawn at least 14 days before starting treatment with guanethidine
Herring, IMAOs
The concomitant intake may cause hypertensive crisis
Histamine dihydrochloride [1], IMAOs ---> SmPC of [1] of EMA
Monoamine oxidase inhibitors, anti-malarial, and anti-trypanosomal active substances may alter the metabolism of histamine dihydrochloride and should be avoided
Human insulin [1], IMAOs ---> SmPC of [1] of EMA
Possible reduction of the patient's insulin requirement
Hydralazine [1], IMAOs ---> SmPC of [1] of eMC
Concurrent treatment of hydralazine with MAOI's may decrease the effects
Hydrocodone, IMAOs
The co-administration of hydrocodone mit MAOI and within 2 weeks after MAOI discontinuation is contraindicated
Hydromorphone [1], IMAOs ---> SmPC of [1] of eMC
Concurrent administration of hydromorphone with monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use is contraindicated
Hydroxychloroquine, IMAOs
Hydroxychloroquine should not be taken with monoamine oxidase inhibitors
Hydroxyzine, IMAOs
Enhancement of anticholinergic effect, hypotension, CNS depression, respiratory function depression. The co-administration is contraindicated
IMAOs [1], pholcodine ---> SmPC of [1] of eMC
Not to be used by patients taking MAOIs or within 14 days of stopping treatment.
IMAOs, imipramine [2] ---> SmPC of [2] of eMC
Imipramine should not be administered for at least 3 weeks after discontinuation of treatment with MAO inhibitors. This also applies when giving a MAO inhibitor after previous treatment with imipramine.
IMAOs, indacaterol/mometasone [2] ---> SmPC of [2] of EMA
This medicinal product should be administered with caution to patients being treated with monoamine oxidase inhibitors, as any effect of these on the QT interval may be potentiated.
IMAOs, indirect sympathomimetics
Patients being treated with a monoamine oxidase inhibitor should not receive indirectly-acting sympathomimetic. In extreme cases interactions may result in severe hypertensive episodes.
IMAOs, insulin
Possible reduction of the insulin requirements
IMAOs, insulin aspart [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements
IMAOs, insulin degludec [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements
IMAOs, insulin degludec/insulin aspart [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements
IMAOs, insulin degludec/liraglutide [2] ---> SmPC of [2] of EMA
Possible reduction of the Xultophy requirements
IMAOs, insulin detemir [2] ---> SmPC of [2] of EMA
Possible reduction of the insulin requirements
IMAOs, insulin glargin [2] ---> SmPC of [2] of EMA
Enhanced blood-glucose-lowering effect and increased susceptibility to hypoglycaemia
IMAOs, insulin glargine/lixisenatide [2] ---> SmPC of [2] of EMA
This substance may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia.
IMAOs, insulin glulisin [2] ---> SmPC of [2] of EMA
Possible enhancement of blood-glucose-lowering activity and increased susceptibility to hypoglycaemia
IMAOs, insulin lispro [2] ---> SmPC of [2] of EMA
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic activity
IMAOs, iohexol
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
IMAOs, iopromide
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
IMAOs, isocarboxazid [2] ---> SmPC of [2] of eMC
Isocarboxazid should not be administered together with other monoamine oxidase inhibitors. Hypotensive and other adverse reactions are likely to be increased.
IMAOs, isoniazid
Mutual enhancement of effects
IMAOs, isoprenaline
Isoprenaline should not be coadministered with MAO inhibitors, due to the combined effect can induce arrythmias
IMAOs, isosorbide dinitrate
Concurrent intake of drugs with blood pressure lowering properties may potentiate the hypotensive effect
IMAOs, labetalol
Enhanced hypotensive effect of the beta-blocker but also the risk of hypertensive crisis. Concomitant use of labetalol and MAO inhibitors is contraindicated
IMAOs, levodopa
Patients being treated with a monoamine oxidase inhibitor should not receive levodopa. In extreme cases interactions may result in severe hypertensive episodes.
IMAOs, levomethadone
Possible severe CNS adverse effects and adverse effects on the respiratory and circulatory function
IMAOs, lisdexamfetamine [2] ---> SmPC of [2] of eMC
Amfetamine should not be administered during or within 14 days following the administration of monoamine oxidase inhibitors (MAOI) because it can increase the release of norepinephrine and other monoamines.
IMAOs, lithium
The combination may precipitate a serotoninergic syndrome, which justifies immediate discontinuation of treatment
IMAOs, lithium carbonate
The combination may precipitate a serotoninergic syndrome, which justifies immediate discontinuation of treatment
IMAOs, lofepramine
Lofepramine should not be administered concurrently with or within 2 weeks of cessation of therapy with monoamine oxidase inhibitors
IMAOs, mazindol
The co-administration of mazindol mit MAOI and within 2 weeks after MAOI discontinuation is contraindicated
IMAOs, melitracen
The co-administration may cause a serotoninergic syndrome. The combination is contraindicated
IMAOs, meprobamate
Meprobamate may increase the effects of concurrently administered central nervous system depressants.
IMAOs, meptazinol
CNS excitation or depression manifesting as hypertension or hypotension may occur if meptazinol is administered to patients receiving MAOIs (including moclobemide). Avoid concomitant use for 14 days after an MAOI is discontinued
IMAOs, mequitazine
The co-administration of mequitazine mit MAOI and within 2 weeks after MAOI discontinuation is contraindicated
IMAOs, metaraminol
The co-administration should be avoided. In extreme cases interactions may result in severe hypertensive episodes
IMAOs, metformin
The co-administration may improve the glucose tolerance and enhance the hypoglycemic effect
IMAOs, methadone [2] ---> SmPC of [2] of eMC
Concurrent administration of methadone with monoamine oxidase inhibitors (including moclobemide) or within 2 weeks of discontinuation of them is contraindicated
IMAOs, methyldopa
The antihypertensive effect of methyldopa may be diminished.
IMAOs, metoclopramide
Metoclopramide release catecholamines in patients with essential hypertension and should be used cautiously with MAOI
IMAOs, metoprolol [2] ---> SmPC of [2] of eMC
Care should be taken when beta-blockers are given in combination MAO inhibitors.
IMAOs, mianserin
The co-administration is contraindicated. Mianserin should not be administrated within 2 weeks before initiating nor after discontinuing a therapy with MAOI
IMAOs, midodrine
The co-administration may cause pronounced hypertension. The combination should be avoided
IMAOs, mirtazapine [2] ---> SmPC of [2] of eMC
Mirtazapine should not be administered concomitantly with MAOI or within 2 weeks after discontinuation of MAOI therapy. In the opposite way about 2 weeks should pass before patients treated with mirtazapine should be treated with MAOI
IMAOs, mivacurium
Drugs that may reduce plasma cholinesterase activity may also prolong the neuromuscular blocking action of mivacurium.
IMAOs, moclobemide [2] ---> SmPC of [2] of eMC
Theoretical pharmacological considerations indicate that MAO inhibitors may precipitate a hypertensive reaction in patients with thyrotoxicosis. As experience in this population group is lacking, caution should be exercised before prescribing moclobemide
IMAOs, morphine [2] ---> SmPC of [2] of eMC
Morphine sulphate should not be co-administered with monoamine oxidase inhibitors or within two weeks of such therapy.
IMAOs, nadolol [2] ---> SmPC of [2] of eMC
Isolated cases of bradycardia have occurred during concurrent use of beta blockers and MAOIs.
IMAOs, naltrexone/bupropion [2] ---> SmPC of [2] of EMA
Since monoamine oxidase A and B inhibitors also enhance the catecholaminergic pathways, by a different mechanism from bupropion, naltrexone / bupropion must not be used with MAOI
IMAOs, naphazoline
Due to the risk of hypertensive crisis, the co-administration is contraindicated and also within the last 2 weeks
IMAOs, naratriptan [2] ---> SmPC of [2] of eMC
Naratriptan does not inhibit monoamine oxidase enzymes; therefore interactions with monoamine oxidase inhibitors are not anticipated.
IMAOs, nateglinide [2] ---> SmPC of [2] of EMA
Monoamine oxidase inhibitors may enhance the hypoglycaemic effect of nateglinide
IMAOs, nicomorphine
The co-administration of opioids with MAO inhibitors may stimulate/inhibit the CNS or induce hypertension or hypotension. The combination is contraindicated or within 2 weeks of discontinuation of MAOI
IMAOs, noradrenaline [2] ---> SmPC of [2] of eMC
The use of noradrenaline with monoamine oxidase inhibitors is not recommended because severe, prolonged hypertension and possible arrhythmias may result
IMAOs, norephedrine
Hypertensive crisis. It is recommended not to use during and until 2 weeks after MAOI therapy
IMAOs, norepinephrine [2] ---> SmPC of [2] of eMC
The use of noradrenaline with monoamine oxidase inhibitors is not recommended because severe, prolonged hypertension and possible arrhythmias may result
IMAOs, norfenefrine
The co-administration is contraindicated and 2 weeks after discontinuation of MAOI
IMAOs, norpseudoephedrine
The indirect sympathomimetic effect of cathine may be dangerously enhanced by MAO inhibitors and during the last 14 days after last taking the MAO inhibitors
IMAOs, nortriptyline [2] ---> SmPC of [2] of eMC
Under no circumstances should nortriptyline be given concurrently with, or within 2 weeks of cessation of, therapy with MAO inhibitors. Hyperpyretic crises, severe convulsions and fatalities have occurred
IMAOs, opiate agonists
The co-administration of opioids with MAO inhibitors may stimulate/inhibit the CNS or induce hypertension or hypotension. The combination is contraindicated or within 2 weeks of discontinuation of MAOI
IMAOs, opicapone [2] ---> SmPC of [2] of EMA
Concomitant use of opicapone with MAO inhibitors (e.g. phenelzine, tranylcypromine and moclobemide) other than those for the treatment of Parkinson's disease is contraindicated.
IMAOs, opicapone [2] ---> SmPC of [2] of EMA
Concomitant use of opicapone and MAO inhibitors for the treatment of Parkinson's disease, e.g. rasagiline (up to 1 mg/day) and selegiline (up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation), is permissible
IMAOs, opioid analgesics ---> SmPC of [alfentanyl] of eMC
The co-administration of opioids with MAO inhibitors may stimulate/inhibit the CNS or induce hypertension or hypotension. The combination is contraindicated or within 2 weeks of discontinuation of MAOI
IMAOs, opipramol
The co-administration is contraindicated. Possible serotoninergic syndrome with severe symptoms. Opipramol should be discontinued 14 days before/after the MAOI therapy
IMAOs, oral antidiabetics
The co-administration may improve the glucose tolerance and enhance the hypoglycemic effect
IMAOs, orciprenaline
Beta-adrenergic agonists should be used with caution in patients treated with MAO inhibitors as the effect of beta-adrenergics may be enhanced
IMAOs, orphenadrine
Concomitant use of other antimuscarinic drugs can lead to an increase in side effects such as dry mouth and urine retention.
IMAOs, oxcarbazepine [2] ---> SmPC of [2] of eMC
The interaction between oxcarbazepine and MAOIs is theoretically possible based on a structural relationship of oxcarbazepine to tricyclic antidepressants.
IMAOs, oxomemazine
Risk of hypertensive crisis or extrapyramidal adverse effects. The co-administration is contraindicated
IMAOs, oxprenolol
The use of MAO inhibitors (except MAO-B inhibitors) with oxprenolol is contraindicated due to the risk of exaggerated hypertension
IMAOs, oxycodone [2] ---> SmPC of [2] of eMC
MAO inhibitors are known to interact with narcotic analgesics, producing CNS excitation or depression with hyper- or hypotensive crisis
IMAOs, oxymetazoline [2] ---> SmPC of [2] of eMC
Oxymetazoline should not be given to patients being treated with monoamine oxidase inhibitors or within 14 days of ceasing such treatment.
IMAOs, pancuronium [2] ---> SmPC of [2] of eMC
Potentiation of the duration of action of pancuronium and the intensity of neuromuscular block.
IMAOs, paroxetine [2] ---> SmPC of [2] of eMC
Concomitant use of paroxetine and MAOIs is contraindicated because of the risk of serotonin syndrome
IMAOs, pentazocine [2] ---> SmPC of [2] of eMC
Monoamine oxidase inhibitors may enhance the opioid effects of pentazocine and the agents may interact through their respective effects on catecholamine breakdown and release.
IMAOs, perhexiline
MAO Inhibitors may enhance the adverse/toxic effect of perhexiline. Avoid concomitant use
IMAOs, periciazine
The co-administration may enhance the hypotensive effect
IMAOs, perphenazine
Concomitant use of perphenazine with drugs inhibiting the metabolism of perphenazine is not recommended.
IMAOs, pethidine ---> SmPC of [rasagiline] of EMA
Serious adverse reactions have been reported with the concomitant use of pethidine and MAO inhibitors including another selective MAO-B inhibitor. The concomitant administration of rasagiline and pethidine is contraindicated
IMAOs, pethidine [2] ---> SmPC of [2] of eMC
The use of pethidine in patients who are receiving, or have within 2 weeks received, monoamine oxidase inhibitors is contraindicated
IMAOs, phenelzine [2] ---> SmPC of [2] of eMC
Phenelzine should not be administered at the same time as, or within 14 days of, treatment with other MAOIs
IMAOs, phenobarbital [2] ---> SmPC of [2] of eMC
Antidepressants may antagonise the antiepileptic activity of phenobarbital by lowering the convulsive threshold
IMAOs, phenothiazines
The concomitant use may prolong or enhance the sedative and anticholinergic effect whether of MAO inhibitor or of phenothiazine
IMAOs, phentermine
The co-administration is contraindicated and during and until 14 days after treatment with a MAOI
IMAOs, phenylephrine
Phenylephrine is contraindicated in patients taking monoamine oxidase inhibitors, or within 14 days of ceasing such treatment
IMAOs, phenylpropanolamine
Hypertensive crisis. It is recommended not to use during and until 2 weeks after MAOI therapy
IMAOs, pindolol
Concurrent use of MAO inhibitors with beta-blockers is not recommended. Possibly significant hypertension may theoretically occur up to 14 days following discontinuation of the MAO inhibitor.
IMAOs, pindolol/clopamide
Concurrent use of MAO inhibitors with beta-blockers is not recommended. Possibly significant hypertension may theoretically occur up to 14 days following discontinuation of the MAO inhibitor.
IMAOs, pioglitazone/glimepiride [2] ---> SmPC of [2] of EMA
Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur
IMAOs, piritramide
The co-administration is contraindicated and during and until 14 days before/after treatment with a MAOI
IMAOs, prazepam
Concomitant use of prazepam and other CNS depressant drugs can mutually enhance the effects
IMAOs, primidone
MAO inhibitors may inhibit the metabolism of primidone and enhance its effect
IMAOs, procyclidine [2] ---> SmPC of [2] of eMC
Drugs with anticholinergic properties may increase the anticholinergic action
IMAOs, promazine
The concomitant administration of promazine with monoamine oxidase inhibitors may result in potentiation of their effects
IMAOs, promethazine
Possible hypertension and enhancement of extrapyramidal motor adverse effects
IMAOs, propantheline
Increased risk of antimuscarinic side effects when antimuscarinics are given with MAOIs
IMAOs, propranolol [2] ---> SmPC of [2] of eMC
The hypotensive effects of beta-blockers may be enhanced by MAOIs.
IMAOs, pseudoephedrine
Hypertensive crisis may occur if pseudoephedrine is co-administered with MAOIs. Concomitant use of, or within 14 days following the administration of, monoamine oxidase inhibitors (MAOI) with pseudoephedrine should be avoided with MAOIs
IMAOs, rasagiline [2] ---> SmPC of [2] of EMA
Concomitant treatment of rasagiline with other monoamine oxidase (MAO) inhibitors is contraindicated. At least 14 days must elapse between discontinuation of rasagiline and initiation of treatment with MAO inhibitors (risk of hypertensive crises)
IMAOs, reboxetine [2] ---> SmPC of [2] of eMC
Concomitant use of MAO-inhibitors and reboxetine should be avoided in view of the potential risk (tyramine-like effect) based on their mechanisms of action.
IMAOs, red wine
The concomitant intake may cause hypertensive crisis
IMAOs, repaglinide [2] ---> SmPC of [2] of EMA
Monoamine oxidase inhibitors (MAOI) may enhance and/or prolong the hypoglycaemic effect of repaglinide.
IMAOs, reproterol
The co-administration with MAO inhibitors may cause increased effect of reproterol on the cardiovascular system
IMAOs, reserpine
The co-administration may cause a severe enhancement of CNS with moderate till severe hypertension. The combination is contraindicated
IMAOs, rilmenidine
The co-administration is not recommended
IMAOs, rizatriptan [2] ---> SmPC of [2] of eMC
Due to a risk of coronary artery vasoconstriction and hypertensive episodes, administration of rizatriptan to patients taking inhibitors of MAO is contraindicated.
IMAOs, safinamide [2] ---> SmPC of [2] of EMA
Safinamide must not be administered along with other MAO inhibitors (including moclobemide) as there may be a risk of non-selective MAO inhibition that may lead to a hypertensive crisis
IMAOs, salbutamol [2] ---> SmPC of [2] of eMC
The effects of salbutamol may be altered by monoamine oxidase inhibitors.
IMAOs, salmeterol
The MAOI may enhance the cardiovascular adverse effects of salmeterol
IMAOs, selegiline [2] ---> SmPC of [2] of eMC
Selegiline should not be given in conjunction with non-specific MAO inhibitors, e.g. linezolid. Concomitant administration of selegiline and MAO inhibitors may cause central nervous and cardiovascular system disorders
IMAOs, serotonin agonists
Potential risk of a serotoninergic syndrome
IMAOs, serotonin reuptake inhibitors
There have been reports of serious reactions (including hyperthermia, rigidity, myoclonic movements and death) when serotonin reuptake inhibitors or serotonin/noradrenaline inhibitors (e.g. venlafaxine) have been combined with MAOIs.
IMAOs, serotonin reuptake inhibitors
There have been reports of serious reactions (including hyperthermia, rigidity, myoclonic movements and death) when serotonin reuptake inhibitors or serotonin/noradrenaline inhibitors (e.g. venlafaxine) have been combined with MAOIs.
IMAOs, serotonin reuptake inhibitors
There have been reports of serious reactions (including hyperthermia, rigidity, myoclonic movements and death) when serotonin reuptake inhibitors or serotonin/noradrenaline inhibitors (e.g. venlafaxine) have been combined with MAOIs.
IMAOs, sertraline
Combination (contraindicated) may cause serious and sometimes fatal reactions. After discontinuing MAOI, wait (depending on IMAO) 5/2 weeks or 1 day before administering SSRI
IMAOs, sibutramine [2] ---> SmPC of [2] of eMC
Two weeks should elapse between stopping sibutramine and starting monoamine oxidase inhibitors.
IMAOs, SNRIs ---> SmPC of [safinamide] of EMA
Serious adverse reactions have been reported with the concomitant use of selective serotonin norepinephrine reuptake inhibitors (SNRIs) and MAO inhibitors
IMAOs, sodium valproate [2] ---> SmPC of [2] of eMC
Valproate may potentiate the effect of other psychotropics; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.
IMAOs, solriamfetol [2] ---> SmPC of [2] of EMA
Solriamfetol must not be administered concomitantly with MAOIs or within 14 days after MAOI treatment has been discontinued because it may increase the risk of a hypertensive reaction
IMAOs, sotalol
Significant blood pressure increase
IMAOs, SSNRI
There have been reports of serious reactions (including hyperthermia, rigidity, myoclonic movements and death) when serotonin reuptake inhibitors or serotonin/noradrenaline inhibitors (e.g. venlafaxine) have been combined with MAOIs.
IMAOs, SSRI ---> SmPC of [fluoxetine] of eMC
Cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with MAOI, and in patients who have recently discontinued an SSRI and have started on a MAOI.
IMAOs, St. John's wort
The co-administration may increase the serotoninergic effects and the adverse reactions. St. John's Wort should be avoided
IMAOs, sufentanil [2] ---> SmPC of [2] of EMA
Discontinuation of MAO inhibitors is generally recommended 2 weeks before treatment with Zalviso, because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
IMAOs, sulfonylureas
The hypoglycaemic action of sulphonylureas in general may be potentiated by monoamine oxidase inhibitors
IMAOs, sumatriptan [2] ---> SmPC of [2] of eMC
An interaction may occur between sumatriptan and monoamine oxidase inhibitors (MAOIs) and concomitant administration is contraindicated
IMAOs, sympathomimetics
Many sympathomimetics interact with MAOIs (possibility of hypertensive crisis), and should not be given to patients receiving such treatment or within 14 days of its termination.
IMAOs, talinolol
The use of MAO inhibitors (except MAO-B inhibitors) with talinolol is contraindicated due to the risk of exaggerated hypertension
IMAOs, tapentadol [2] ---> SmPC of [2] of eMC
Treatment with tapentadol should be avoided in patients who are receiving MAO inhibitors or who have taken them within the last 14 days due to potential additive effects on synaptic noradrenaline concentrations
IMAOs, tedizolid [2] ---> SmPC of [2] of EMA
Tedizolid is a reversible inhibitor of monoamine oxidase (MAO) in vitro; however, no interaction is anticipated when comparing the IC50 for MAO-A inhibition and the anticipated plasma exposures in man.
IMAOs, terbutaline
The co-administration may enhance the effect of terbutaline on the cardiovascular system
IMAOs, tetrabenazine
Possible state of central excitement and hypertension. Contraindicated. It is recommended an interval of at least 2 weeks between each one
IMAOs, tetryzoline
Concomitant use of tetryzoline with MAO inhibitors may enhance the vasoconstrictor effect and increase the blood pressure. The co-administration is contraindicated
IMAOs, thioridazine
The concomitant use may prolong or enhance the sedative and anticholinergic effect whether of MAO inhibitor or of phenothiazine
IMAOs, tianeptine
Tianeptine should not be used with MAO inhibitors due to the risk of cardiovascular collapse, paroxysmal hypertension, hyperthermia, seizures and dead
IMAOs, tilidine
Increased risk of respiratory depression. The co-administration is contraindicated and until 2 weeks after discontinuation of a MAOI
IMAOs, timolol
The potential exists for additive effects and production of hypotension and/or marked bradycardia.
IMAOs, tolbutamide
Increased hypoglycaemic effects have occurred or might be expected
IMAOs, tramadol [2] ---> SmPC of [2] of eMC
Concomitant therapeutic use of tramadol and serotonergic drugs, such as MAO inhibitors, may cause serotonin toxicity. The combination of tramadol with MAO inhibitors or within 2 weeks of their withdrawal is contraindicated
IMAOs, tramazoline
Concomitant use of tramazoline and MAO inhibitors of tranylcypromine type may increase the blood pressure. Concomitant use should be avoided
IMAOs, trazodone [2] ---> SmPC of [2] of eMC
Use of trazodone with MAOIs, or within 2 weeks of stopping treatment with these compounds is not recommended. The giving of MAOIs within 1 week of stopping trazodone is also not recommended.
IMAOs, triamterene [2] ---> SmPC of [2] of eMC
The co-administration of triamterene and MAOIs may enhance the hypotensive effect
IMAOs, tricyclic antidepressant ---> SmPC of [safinamide] of EMA
Serious adverse reactions have been reported with the concomitant use of tricyclic antidepressants and MAO inhibitors
IMAOs, trihexyphenidyl
Monoamine oxidase inhibitors can interact with concurrently administered anticholinergic agents. This can cause dry mouth, blurred vision, urinary hesitancy, urinary retention and constipation.
IMAOs, trimipramine [2] ---> SmPC of [2] of eMC
Trimipramine should not be given concurrently with, or within 2 weeks of cessation of, therapy with monoamine oxidase inhibitors.
IMAOs, triptans ---> SmPC of [almotriptan] of eMC
As with other 5-HT1 agonists, the potential risk of a serotoninergic syndrome due to a pharmacodynamic interaction in case of concomitant treatment of almotriptan with MAOIs cannot be ruled out.
IMAOs, tryptophan
The co-administration can cause serotoninergic syndrome. The combination is contraindicated
IMAOs, tyramine
Patients being treated with a monoamine oxidase inhibitor should not receive tyramine. In extreme cases interactions may result in severe hypertensive episodes.
IMAOs, valproic acid [2] ---> SmPC of [2] of eMC
Valproate may potentiate the effect of other psychotropics; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.
IMAOs, venlafaxine
Combination (contraindicated) may cause serious and sometimes fatal reactions. After discontinuing MAOI, wait (depending on IMAO) 5/2 weeks or 1 day before administering SSRI
IMAOs, vilazodone
Combination (contraindicated) may cause serious and sometimes fatal reactions. After discontinuing MAOI, wait (depending on IMAO) 5/2 weeks or 1 day before administering SSRI
IMAOs, xylometazoline [2] ---> SmPC of [2] of eMC
As for all sympathomimetics, a reinforcement of the systemic effects of xylometazoline by concomitant use of monoamine oxidase inhibitors cannot be excluded, especially in case of overdose.
IMAOs, yeast
Possible increased blood pressure
IMAOs, zimeldine
Combination (contraindicated) may cause serious and sometimes fatal reactions. After discontinuing MAOI, wait (depending on IMAO) 5/2 weeks or 1 day before administering SSRI